Chiusura precedente | 94,36 |
Aperto | 93,60 |
Denaro | 0,00 x 0 |
Lettera | 0,00 x 0 |
Min-Max giorno | 93,50 - 93,84 |
Intervallo di 52 settimane | 72,94 - 104,70 |
Volume | |
Media Volume | 9.934 |
Capitalizzazione | 81,226B |
Beta (5 anni mensile) | 0,72 |
Rapporto PE (ttm) | 34,03 |
EPS (ttm) | 2,79 |
Prossima data utili | 23 ott 2023 - 27 ott 2023 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
EAGAN, Minn., June 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of Dr. Bernard A. Harris, Jr. to its newly-formed
WASHINGTON, April 24, 2023 (GLOBE NEWSWIRE) -- Fuse Integration, a warfighter-focused engineering and design firm, and Raytheon Technologies, a leading aerospace and defense company that provides advanced systems and services for commercial, military and government customers worldwide, today announced that the U.S. Department of Defense has recognized the companies with a prestigious 2022 Nunn-Perry Award for excellence in the DoD Mentor-Protégé Program. The award recognizes collaboration suppor